0000899243-17-026034.txt : 20171113
0000899243-17-026034.hdr.sgml : 20171110
20171113162722
ACCESSION NUMBER: 0000899243-17-026034
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171113
FILED AS OF DATE: 20171113
DATE AS OF CHANGE: 20171113
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: venBio Global Strategic Fund II L.P.
CENTRAL INDEX KEY: 0001634632
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38276
FILM NUMBER: 171196255
BUSINESS ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 415-522-0100
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001492422
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 271537290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6400 WESTWIND WAY
STREET 2: SUITE A
CITY: CRESTWOOD
STATE: KY
ZIP: 40014
BUSINESS PHONE: 502-241-4114
MAIL ADDRESS:
STREET 1: 6400 WESTWIND WAY
STREET 2: SUITE A
CITY: CRESTWOOD
STATE: KY
ZIP: 40014
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-11-13
1
0001492422
Apellis Pharmaceuticals, Inc.
APLS
0001634632
venBio Global Strategic Fund II L.P.
1700 OWENS STREET, SUITE 595
SAN FRANCISCO
CA
94158
0
0
1
0
Common Stock
2017-11-13
4
C
0
3451790
A
3451790
D
Common Stock
2017-11-13
4
P
0
127515
14.00
A
3579305
D
Series D Preferred Stock
2017-11-13
4
C
0
6714413
0.00
D
Common Stock
3147872
0
D
Series E Preferred Stock
2017-11-13
4
C
0
648256
0.00
D
Common Stock
303917
0
D
The Series D and Series E Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D and Series E Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
Robert Adelman and Corey Goodman, the managing partners of venBio Global Strategic Fund II LP ("venBio"), share voting and dispositive control over the shares held by venBio.
/s/ Robert Adelman
2017-11-13